Neurogene (NASDAQ:NGNE) Earns Buy Rating from Analysts at HC Wainwright
HC Wainwright assumed coverage on shares of Neurogene (NASDAQ:NGNE – Free Report) in a research note released on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $45.00 price target on the stock. HC Wainwright also issued estimates for Neurogene’s Q4 2023 earnings at ($1.66) EPS, FY2023 earnings at ($7.82) EPS, Q1 […]
More Stories
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Sees Large Increase in Short Interest
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Free Report) was the target of a significant increase in short interest in December....
Analysts Set IDEXX Laboratories, Inc. (NASDAQ:IDXX) Price Target at $539.63
IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten analysts...
KULR Technology Group Increases Offering Amount by $50 Million
On December 26, 2024, KULR Technology Group, Inc. (NYSEAMERICAN:KULR) announced that it has entered into an amendment with Craig-Hallum Capital...
NexPoint Real Estate Finance Announces Changes in Executive Leadership
On December 24, 2024, NexPoint Real Estate Finance, Inc. (NYSE: NREF) disclosed in an 8-K filing with the Securities and...
Coeptis Therapeutics Holdings, Inc. Announces Reverse Stock SplitWEXFORD, PA., Dec. 27, 2024 – Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) disclosed its plans to undergo a 1-for-40 reverse stock split (the “Reverse Split”) for its common stock
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
Bespoke Extracts Enters into Securities Purchase Agreements with Accredited Investors
On December 18, 2024, Bespoke Extracts, Inc. (OTCMKTS:BSPK) announced that it had entered into securities purchase agreements with several non-affiliated...